Salivary Gland Cancer

In conclusion, intratumoral Tregs and peritumoural T lymphocytes may be used as negative prognostic biomarkers. Future multicentric studies and AI (Artificial Intelligence)-driven analyses could enhance immune characterization and guide immunotherapeutic strategies in SGC.

These advances underscore the growing role of molecular diagnostics in improving accuracy, guiding prognostication, and refining the classification of rare ocular tumors. As high-throughput techniques continue to mature, integration with evolving spatial and single-cell-based approaches promises to expand our understanding and further personalize diagnostic and therapeutic strategies.

The tumor progressed after two cycles of first-line induction chemotherapy with paclitaxel plus cisplatin. The response to disitamab vedotin, despite prior taxane progression, suggests the potential critical role of HER2-mediated drug delivery and indicates that low antigen density may be sufficient for ADC efficacy. This case indicates the importance of routine HER2 testing with explicit HER2-low categorization in advanced SGCs and offers preliminary evidence that may help expand therapeutic options for this treatment-refractory population.

After adjuvant chemotherapy, maintenance larotrectinib was initiated based on proven TRK inhibitor efficacy in metastatic NTRK-fusion tumors and emerging evidence for targeted therapy benefit in driver-positive early stage lung adenocarcinoma. Our findings demonstrate the value of molecular pathology in the diagnostic journey of pulmonary malignancies, guiding rare fusion detection and supporting therapeutic decisions based on rare fusions in early stage disease.

While the primary end point of best ORR was not met in this nonrandomized clinical trial, amivantamab was well tolerated, and most patients exhibited disease stabilization. ClinicalTrials.gov Identifier: NCT05074940.

With an 88% success rate, the first ACC organoid platform, incorporating normal salivary gland (SG) organoids as toxicity controls, enabled high-throughput drug testing within two weeks. In conclusion, we developed an efficient culture system for ACC organoids that can preserve tumor heterogeneity and establish a reliable drug screening platform for mechanistic studies and personalized precision therapy research.

P2, N=55, Recruiting, Dana-Farber Cancer Institute | Trial completion date: Feb 2027 --> Feb 2029 | Trial primary completion date: Feb 2026 --> Feb 2028

Revisiting her history revealed a diagnosis of a benign salivary gland tumor in the left parotid, which was surgically removed almost 40 years ago. This piece of clinical information put the morphology into perspective and subsequent molecular testing detected an unusual PLAG1 gene rearrangement, confirming the diagnosis of a benign metastasizing PA in this unique case.

Histopathology and immunohistochemistry are the best myoepithelioma diagnostic methods. Malignant myoepithelioma must be ruled out by thorough invasion testing.

P2, N=46, Active, not recruiting, Alliance for Clinical Trials in Oncology | Trial completion date: Jul 2022 --> Jul 2028

The diagnosis required pathology and molecular testing. MAML2 rearrangement suggests a better prognosis; further research is needed to elucidate its pathogenesis and improve its treatment.

P=N/A, N=600, Recruiting, Ohio State University Comprehensive Cancer Center | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026